GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BIOAGE Labs BIOA · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.69

+6.55%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$9.0m

FY2014FY2025

Net income

−$80.6m

FY2014FY2025

Free cash flow

−$82.3m

FY2014FY2025

Shareholders' equity

$272.1m

FY2014FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2017FY2016FY2015FY2014
Revenue$9.0m———$14.9m$8.3m$2.2m$1.5m
Research and development$74.0m$59.0m$33.9m$30.5m$5.5m$7.2m$20.3m$15.2m
Operating income−$92.8m−$78.2m−$48.4m−$40.0m−$110.0m−$29.6m−$38.5m−$35.2m
Net income−$80.6m−$71.1m−$63.9m−$39.7m−$98.2m−$22.5m−$37.2m−$46.4m
Diluted earnings per share-2.23-1.98-1.87-1.16-2.34-0.66-1.32-1.65

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2017FY2016FY2015FY2014
Total assets$294.9m$358.2m$25.9m$28.4m$69.5m$161.3m$143.1m$152.4m
Cash and short-term investments$281.1m$354.3m$21.6m$27.6m$4.6m$16.2m$7.0m$51.0m
Total liabilities$22.8m$35.1m$199.3m$141.0m$47.7m$112.8m$96.7m$94.9m
Debt$3.2m$8.5m$53.1m$2.4m$4.9m$23.3m$10.3m$3.0m
Shareholders' equity$272.1m$323.1m−$173.4m−$112.6m$21.9m$48.5m$46.4m$57.5m
Shares outstanding36m36m34m34m42m34m28m28m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2017FY2016FY2015FY2014
Cash from operations−$81.6m−$51.5m−$37.4m−$36.2m−$29.8m−$37.6m−$32.2m−$22.5m
Capital spending−$719,000−$366,000−$166,000−$103,000————
Free cash flow−$82.3m−$51.9m−$37.5m−$36.3m−$29.8m−$37.6m−$32.2m−$22.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$2.5m$2.8m$3.1m$2.1m$2.4m$1.5m——
Operating income−$29.3m−$25.4m−$28.4m−$23.1m−$24.8m−$16.4m−$25.4m−$24.8m
Net income−$26.1m−$22.3m−$25.9m−$20.2m−$21.6m−$12.9m−$21.1m−$23.4m
Diluted earnings per share-0.58-0.50-0.72-0.56-0.60-0.36-0.59-0.65
Cash from operations−$19.0m−$24.0m−$28.0m−$16.0m−$19.0m−$17.0m−$5.0m−$14.0m
Total assets$396.9m$397.7m$294.9m$305.1m$322.1m$343.8m$358.2m$337.4m
Cash and short-term investments$318.7m$383.2m$281.1m$285.8m$297.3m$320.5m$354.3m$334.5m
Debt$714,000$1.8m$3.2m$4.7m$6.2m$7.8m$8.7m$10.2m
Shareholders' equity$374.9m$379.1m$272.1m$277.5m$294.8m$313.2m$323.1m$313.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue—1.7%—
Operating income32.4%25.6%—
Net income26.6%29.1%—

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-2.2-1.1
Price to sales19.3—

Share price return

Finished calendar years

20252024
Return188%1%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.